About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Dapagliflozin Tab

Company: Sherihan AboElyazed Mohamed Khalil
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 24, 2026

Trial details

Completed NCT NCT04240171

Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

Damanhour University 60 participants Est. completion 2022-01-31 1 site

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07891234

Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance

Not yet reported Sherihan AboElyazed Mohamed Khalil 66 participants Est. completion 2027-10-01 1 site

Prediabetes
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07891234

Also known as: Dapagliflozin Tab, Dapagliflozin 5Mg Tab, PreDM/Dapa

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.